Fangqian Li

mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial

L. Kang, Xiaojian Wu, Yunle Wan, 2021, Annals of translational medicine.

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.

M. Qiu, L. Kang, Xiaojian Wu, 2020, The oncologist.

Baseline and early 3D-CUBE volume reconstruction of locally advanced rectal cancer to predict tumor response after neoadjuvant chemotherapy.

W. Cao, Wenli Li, Zhi-yang Zhou, 2020, Journal of X-ray science and technology.

Rectal cancer restaging using 3D CUBE vs. 2D T2-weighted technique after neoadjuvant therapy: a diagnostic study

W. Cao, Yan-bang Lian, Zhi-yang Zhou, 2016, Gastroenterology report.

Liver acquisition with acceleration volume acquisition gadolinium-enhanced magnetic resonance combined with T2 sequences in the diagnosis of local recurrence of rectal cancer.

L. Kang, W. Cao, Zhi-yang Zhou, 2016, Journal of X-ray science and technology.